FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379330336> ?p ?o ?g. }

• W4379330336 endingPage "e17590" @default.
• W4379330336 startingPage "e17590" @default.
• W4379330336 abstract "e17590 Background: Along with residual disease after surgery, response to platinum therapy is a key prognostic indicator in patients with advanced OC. It is a prerequisite for receiving PARP inhibitor maintenance therapy and directs future treatment choices. Our objective was to describe differences in characteristics and outcomes between patients with platinum resistance (PR) or PST in a community oncology setting. Methods: This was a retrospective study of adult female patients with advanced OC (Stage III/IV) who received 4+ cycles of a 1L platinum-based regimen during 01/01/2017 to 06/30/2021 (followed until 12/31/2021) and had ≥ 2 visits within The US Oncology Network. Patients who were platinum resistant (PR, relapse 30 days to < 6 months after platinum discontinuation) or PST (relapse at 6+ months after platinum discontinuation) were included; refractory patients (relapse during or within 30 days of platinum discontinuation) were excluded. Structured and chart review data were used. Multivariable logistic regression assessed the association of factors with PST vs. PR. Results: In total 142 patient charts (108 PST, 34 PR) were reviewed. In addition to platinum-based chemotherapy, 19% of patients also initiated bevacizumab. Most patients were White (63%), diagnosed at Stage IIIC (55%) or IV (33%), and had epithelial OC (82%). Overall, 52%, 23% and 25% of patients had ECOG performance status scores of 0/1, 2+ and not documented, respectively. BRCA status was positive for 7.7% but not documented for 38%, and Charlson comorbidity score (CCS) was 0 for 63% of patients. PST vs. PR patients were younger, 69 (27-90+) years vs. 71 (51-89) [median (range), p = 0.045]. More PST vs. PR patients were normal weight (40% vs. 29%) or overweight (30% vs. 15%) and fewer were obese (24% vs. 41%) (p = 0.011). In multivariable adjusted analysis (excluding underweight and unreported BMI categories for low counts), Stage IV vs. III (p = 0.003) was associated with significantly higher odds of PR after 1L, while obesity vs. healthy weight (p = 0.067) and ECOG 2+ vs. 0/1 (p = 0.057) were associated with numerically higher odds of PR after 1L; age, CCS and 1L bevacizumab use were not associated with PST. Kaplan-Meier median (95% confidence interval [CI]) overall survival in PST vs. PR was not reached [NR] (44.6, NR) vs. 16.7 (13.9, 23.6) months while median (95% CI) progression-free survival was 19.6 (17.6,24.9) months vs.7.9 (7.1,8.5) months, respectively. Conclusions: When exploring factors associated with response to 1L platinum-based treatment of OC adjusting for other factors, higher stage was significantly associated with PR, while patients with obesity and poor ECOG status had nonsignificantly greater odds of PR. PR patients have poorer survival and fewer treatment options, and standard of care treatment of 1L OC in these subgroups should be further explored to address this unmet need." @default.
• W4379330336 created "2023-06-05" @default.
• W4379330336 creator A5003839820 @default.
• W4379330336 creator A5025133222 @default.
• W4379330336 creator A5035234582 @default.
• W4379330336 creator A5057287935 @default.
• W4379330336 creator A5070198399 @default.
• W4379330336 creator A5072428592 @default.
• W4379330336 date "2023-06-01" @default.
• W4379330336 modified "2023-09-25" @default.
• W4379330336 title "Factors associated with platinum sensitivity (PST) and related outcomes in patients with ovarian cancer (OC) in a US community oncology setting: Looking beyond." @default.
• W4379330336 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.e17590" @default.
• W4379330336 hasPublicationYear "2023" @default.
• W4379330336 type Work @default.
• W4379330336 citedByCount "0" @default.
• W4379330336 crossrefType "journal-article" @default.
• W4379330336 hasAuthorship W4379330336A5003839820 @default.
• W4379330336 hasAuthorship W4379330336A5025133222 @default.
• W4379330336 hasAuthorship W4379330336A5035234582 @default.
• W4379330336 hasAuthorship W4379330336A5057287935 @default.
• W4379330336 hasAuthorship W4379330336A5070198399 @default.
• W4379330336 hasAuthorship W4379330336A5072428592 @default.
• W4379330336 hasConcept C121332964 @default.
• W4379330336 hasConcept C121608353 @default.
• W4379330336 hasConcept C126322002 @default.
• W4379330336 hasConcept C141071460 @default.
• W4379330336 hasConcept C142424586 @default.
• W4379330336 hasConcept C143998085 @default.
• W4379330336 hasConcept C167135981 @default.
• W4379330336 hasConcept C2776694085 @default.
• W4379330336 hasConcept C2778239845 @default.
• W4379330336 hasConcept C2778715236 @default.
• W4379330336 hasConcept C2781413609 @default.
• W4379330336 hasConcept C2781451048 @default.
• W4379330336 hasConcept C71924100 @default.
• W4379330336 hasConcept C87355193 @default.
• W4379330336 hasConceptScore W4379330336C121332964 @default.
• W4379330336 hasConceptScore W4379330336C121608353 @default.
• W4379330336 hasConceptScore W4379330336C126322002 @default.
• W4379330336 hasConceptScore W4379330336C141071460 @default.
• W4379330336 hasConceptScore W4379330336C142424586 @default.
• W4379330336 hasConceptScore W4379330336C143998085 @default.
• W4379330336 hasConceptScore W4379330336C167135981 @default.
• W4379330336 hasConceptScore W4379330336C2776694085 @default.
• W4379330336 hasConceptScore W4379330336C2778239845 @default.
• W4379330336 hasConceptScore W4379330336C2778715236 @default.
• W4379330336 hasConceptScore W4379330336C2781413609 @default.
• W4379330336 hasConceptScore W4379330336C2781451048 @default.
• W4379330336 hasConceptScore W4379330336C71924100 @default.
• W4379330336 hasConceptScore W4379330336C87355193 @default.
• W4379330336 hasIssue "16_suppl" @default.
• W4379330336 hasLocation W43793303361 @default.
• W4379330336 hasOpenAccess W4379330336 @default.
• W4379330336 hasPrimaryLocation W43793303361 @default.
• W4379330336 hasRelatedWork W1969833561 @default.
• W4379330336 hasRelatedWork W1983784941 @default.
• W4379330336 hasRelatedWork W2022084568 @default.
• W4379330336 hasRelatedWork W2059792707 @default.
• W4379330336 hasRelatedWork W2289428780 @default.
• W4379330336 hasRelatedWork W23962071 @default.
• W4379330336 hasRelatedWork W2473626106 @default.
• W4379330336 hasRelatedWork W2528057197 @default.
• W4379330336 hasRelatedWork W3104230093 @default.
• W4379330336 hasRelatedWork W4231341789 @default.
• W4379330336 hasVolume "41" @default.
• W4379330336 isParatext "false" @default.
• W4379330336 isRetracted "false" @default.
• W4379330336 workType "article" @default.